By Nana O 
In a pivotal clinical study, researchers from the Texas Biomedical Device Center (TxBDC) at The University of Texas at Dallas have demonstrated unprecedented rates of recovery for spinal cord injuries, offering a beacon of hope for individuals previously facing limited treatment options. The findings, published in the prestigious journal Nature on May 21st, detail a novel approach that combines targeted nerve stimulation with progressive, individualized rehabilitation, yielding significant improvements in upper-limb function for those with incomplete spinal cord injuries.
This innovative therapy, termed closed-loop vagus nerve stimulation (CLV), represents the culmination of over a decade of dedicated neuroscience and bioengineering research at UT Dallas. The treatment involves the precise delivery of electrical pulses to the brain via a miniaturized implant in the neck, synchronized with rehabilitative exercises. Unlike previous studies where vagus nerve stimulation augmented existing recovery from therapy, this research marks a critical divergence: for spinal cord injury patients in this trial, therapy alone yielded no discernible improvements, underscoring the unique efficacy of the CLV approach.
The Genesis of a Revolutionary Therapy
The journey toward this breakthrough began with a fundamental understanding of neuroplasticity. UT Dallas investigators had previously established that stimulating the vagus nerve during physical therapy could promote rewiring of brain areas affected by stroke, leading to enhanced recovery of motor function. This foundational knowledge paved the way for exploring its application in the more complex landscape of spinal cord injury.
Dr. Michael Kilgard, the Margaret Fonde Jonsson Professor of Neuroscience at UT Dallas and the study’s corresponding author, elucidated the distinction between treating stroke and spinal cord injury. "In stroke, individuals who undergo therapy often see some improvement, and adding CLV amplifies that progress," Dr. Kilgard explained. "However, this study is fundamentally different: therapy alone for spinal cord injury did not yield any benefits for our participants. The CLV intervention was the catalyst for any gains."
The development of the CLV device itself is a testament to bioengineering innovation. Dr. Robert Rennaker, professor of Neuroscience and the Texas Instruments Distinguished Chair in Bioengineering, designed the miniature implantable device. "These activities allow patients to regain strength, speed, range of motion, and hand function. They simplify daily living," Dr. Rennaker stated, highlighting the practical implications of the restored capabilities. The latest iteration of this device is remarkably small – approximately 50 times smaller than its predecessor from three years ago – and is designed to be compatible with MRI, CT scans, and ultrasounds, minimizing patient inconvenience and expanding diagnostic possibilities.
Clinical Trial Design and Unprecedented Results
The clinical trial, which served as both a Phase 1 and Phase 2 study, enrolled 19 participants diagnosed with chronic, incomplete cervical spinal cord injuries. Over a 12-week period, each participant engaged in a regimen of simple video games designed to elicit specific upper-limb movements. The CLV implant was activated only upon successful execution of these movements, creating a direct feedback loop that reinforced neural pathways.
The results were nothing short of remarkable. Participants experienced significant improvements in arm and hand strength, as well as enhancements in speed, range of motion, and overall hand function. Crucially, these gains translated into tangible improvements in their ability to perform daily living activities.
The study incorporated a randomized placebo-controlled element in its initial phase. Nine of the 19 participants received sham stimulation for the first 18 therapy sessions, followed by active CLV treatment for the subsequent 18 sessions. This rigorous design allowed researchers to isolate the effects of CLV and confirm its efficacy.
The participant demographics underscored the broad applicability of the treatment. Ages ranged from 21 to 65 years, and the time elapsed since injury varied from one to 45 years. Significantly, neither the age of the participants nor the duration or severity of their impairment (provided there was some residual hand movement) influenced the degree of their response to the CLV therapy.
A Paradigm Shift in Spinal Cord Injury Treatment
Dr. Jane Wigginton, a medical doctor and Chief Medical Officer at TxBDC, co-director of UT Dallas’s Clinical and Translational Research Center, and medical science research director at the Center for BrainHealth, emphasized the medical significance of these findings. "This approach produces results regardless of these factors, which often cause significant differences in success rates of other types of treatment," Dr. Wigginton stated. Her role in planning the clinical interactions and ensuring patient protections was critical to the trial’s success. "It is remarkable from a medical standpoint," she added.
TxBDC’s extensive research into CLV over 13 years has already led to FDA approval for treating impaired upper-limb movement in stroke patients. However, the success in spinal cord injury patients represents a particularly exciting advancement, as it addresses a population for whom effective treatment options have been severely limited. "The people in this study have now gained the ability to do things that are meaningful for them and impactful in their lives," Dr. Wigginton commented, underscoring the profound life-changing potential of this therapy.
The Path Forward: From Promising Results to FDA Approval
The successful completion of this combined Phase 1 and 2 trial positions the UT Dallas scientists to advance to a pivotal Phase 3 trial. This next stage is the final regulatory hurdle before potential Food and Drug Administration (FDA) approval for the treatment of upper-limb impairment resulting from spinal cord injury.
Dr. Seth Hays, an associate professor of bioengineering and a Fellow of the Eugene McDermott Distinguished Professor in the Erik Jonsson School of Engineering and Computer Science, has been involved with the CLV project since its inception. "Prior to this study, no person with spinal cord injury had ever received CLV," he noted. "This is the first evidence that gains can be made. Now we will set about determining how we make this optimally effective."
Dr. Hays, however, also offered a measured perspective on the road ahead. "We still have a long road ahead," he cautioned. "For many reasons — financial, regulatory, or scientific — this could still die on the vine. But we have positioned ourselves to succeed." The upcoming Phase 3 trial is designed to be a larger, multi-institutional study involving approximately 70 participants at leading U.S. centers specializing in spinal cord injury care. This broader scope will further validate the efficacy and safety of the CLV therapy across diverse patient populations and clinical settings.
A Collaborative Effort with Profound Implications
The research team consistently emphasized the critical contributions of numerous individuals and institutions. The unwavering dedication of the patients who participated in the study was paramount. Their willingness to undergo experimental treatment and actively engage in rehabilitation demonstrated immense courage and commitment.
"These patients said, ‘Put that device in me’ — that’s a huge commitment," remarked Dr. Rennaker. "They deserve credit for paving the path for others."
Beyond the patients, TxBDC acknowledged the invaluable collaboration with its partners: Baylor University Medical Center, Baylor Scott & White Research Institute, and Baylor Scott & White Institute for Rehabilitation. This multidisciplinary collaboration ensured the highest standards of patient care, ethical conduct, and scientific rigor throughout the trial.
"This has been the hardest working, most altruistic group of professionals, and that has been incredibly impactful," said Dr. Wigginton, reflecting on the collaborative spirit that defined the project.
The broader implications of this research extend far beyond the immediate improvements in arm and hand function. For individuals with spinal cord injuries, particularly those with chronic conditions where functional recovery is often limited, this therapy offers the potential for a significantly improved quality of life. Regaining the ability to perform everyday tasks, engage in hobbies, and maintain independence can have profound psychological and social benefits, reducing reliance on caregivers and fostering a greater sense of autonomy.
Furthermore, the success of CLV in spinal cord injury treatment could pave the way for its application in other neurological conditions characterized by motor impairment. The underlying principle of enhancing neuroplasticity through targeted stimulation and rehabilitation is a versatile concept with potential to address a spectrum of debilitating conditions.
Funding and Future Directions
The groundbreaking research was made possible through significant funding from the Defense Advanced Research Projects Agency (DARPA), an agency of the Department of Defense, via grant number N66001-17-2-4011, and the Wings for Life Accelerated Translational Program. This support underscores the national interest in developing innovative solutions for complex medical challenges.
Several UT Dallas-affiliated researchers contributed significantly to the study, including Joseph Epperson, a TxBDC research associate; Emmanuel Adehunoluwa, a cognition and neuroscience doctoral student; Amy Porter, TxBDC Director of Operations; Holle Carey Gallaway, TxBDC research biomedical engineer; and David Pruitt, who holds multiple degrees from UTD.
It is important to note that researchers involved in the CLV project also have financial interests in related commercial ventures. Dr. Kilgard has a financial interest in MicroTransponder Inc., a company that markets vagus nerve stimulation therapy for stroke. Dr. Rennaker is the founder and CEO of XNerve, the company that developed the device used in this spinal cord injury study. These disclosures are standard practice in scientific research and are managed to ensure ethical conduct and transparency.
As the scientific community awaits the results of the Phase 3 pivotal trial, the findings from this initial study represent a monumental step forward. The unprecedented recovery rates demonstrated by CLV offer tangible hope for a future where spinal cord injuries, once considered irreversible, can be effectively treated, restoring function and profoundly improving the lives of countless individuals.
